NCT06142396 2026-03-12
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Phase EARLY_PHASE1 Recruiting
Clinical Trials
19 trialsNCT05093335 2026-02-05
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT06663046 2026-01-20
Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Recruiting
NCT07336823 2026-01-13
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd.
Phase EARLY_PHASE1 Recruiting
NCT06385652 2026-01-06
PET Imaging Study of 68Ga-NB381 in Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT07294625 2025-12-19
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Recruiting
NCT07249073 2025-11-25
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT07101705 2025-09-09
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT06988059 2025-08-01
A Study of CT0596 in Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT06976437 2025-07-10
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Affiliated Hospital of Jiangsu University
Phase EARLY_PHASE1 Recruiting
NCT06717113 2025-06-06
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Peking University First Hospital
Phase EARLY_PHASE1 Recruiting
NCT06691685 2025-03-25
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1 Recruiting
NCT06209606 2024-12-17
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
Oncotherapeutics
Phase EARLY_PHASE1 Recruiting
NCT06732232 2024-12-13
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT06718270 2024-12-12
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT06407947 2024-06-12
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Shanghai Changzheng Hospital
Phase EARLY_PHASE1 Recruiting
NCT04657861 2022-05-09
APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04662294 2021-11-04
CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT04603872 2020-10-28
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Zhejiang University
Phase EARLY_PHASE1 Recruiting